Literature DB >> 21842362

KIR/HLA: genetic clues for a role of NK cells in the control of HIV.

Lena Fadda, Galit Alter.   

Abstract

Early events following HIV infections determine the course of disease progression. Mounting evidence suggests that antiviral immune responses induced soon after infection, prior to the induction of adaptive immune responses, are key to early control of viral infection. Among the early innate immune effector cells, natural killer (NK) cells represent a unique subset of lymphoctyes that do not express an antigen specific receptor. Rather, these cells integrate signals from an arsenal of non-specific inhibitory and activating receptors that are expressed on their cell surface. As such, these cells are classified as cells of the innate immune system, and they are able to lyse certain tumor targets and infected cells without the need for prior antigen sensitization. Over the past decade, accumulating evidence suggests that these innate lymphocytes may not be as innate as once believed, but that individual NK cell clones may show some target cell specificity, and play a critical early role following infection with HIV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21842362     DOI: 10.1007/978-1-4419-5632-3_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  4 in total

Review 1.  Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Authors:  Nichole R Klatt; Nicolas Chomont; Daniel C Douek; Steven G Deeks
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

2.  Modest attenuation of HIV-1 Vpu alleles derived from elite controller plasma.

Authors:  Jingyan Chen; Nadine Tibroni; Daniel Sauter; Johanna Galaski; Toshiyuki Miura; Galit Alter; Birthe Mueller; Claudia Haller; Bruce D Walker; Frank Kirchhoff; Zabrina L Brumme; Takamasa Ueno; Oliver T Fackler
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 3.  Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.

Authors:  Dongfang Liu; Shuo Tian; Kai Zhang; Wei Xiong; Ndongala Michel Lubaki; Zhiying Chen; Weidong Han
Journal:  Protein Cell       Date:  2017-05-09       Impact factor: 14.870

4.  Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

Authors:  Asifa Zaidi; Qinglai Meng; Daniel Popkin
Journal:  Immunotherapy (Los Angel)       Date:  2015-11-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.